Search results
Results from the WOW.Com Content Network
Tay–Sachs disease, which can present as a fatal illness of children that causes mental deterioration prior to death, was historically extremely common among Ashkenazi Jews, [19] with lower levels of the disease in some Pennsylvania Dutch, Italian, Irish Catholic, and French Canadian descent, especially those living in the Cajun community of ...
Ashkenazi Jews have been screened as Tay–Sachs carriers since carrier testing began in 1971. Since the 1970s, many Jewish communities have embraced genetic screening, and in 1971, Israel became the first country to offer free genetic screening [1] and counseling for Tay–Sachs disease and other diseases, leading to international discussion about the proper scope of genetic testing.
Ashkenazi Jews have a high incidence of Tay–Sachs and other lipid storage diseases. In the United States, about 1 in 27 to 1 in 30 Ashkenazi Jews is a recessive carrier. The disease incidence is about 1 in every 3,500 newborns among Ashkenazi Jews. [39]
Researchers suggest their study challenges the previous view that disease-related variants associated with Ashkenazi Jewish populations only became more common in the past 600 years.
The question of whether Jews constitute a "pure race" or a "mixed race" was under debate, and Tay–Sachs disease was seen as evidence of a Jewish racial type, which was believed to have a predilection for neurological disorders. [4] Even the Jewish Encyclopedia reflected such a characterization of Tay–Sachs disease: [3]
Dor Yeshorim (Hebrew: דור ישרים) also called Committee for Prevention of Jewish Genetic Diseases, is a nonprofit organization that offers genetic screening to members of the Jewish community worldwide. Its objective is to minimize, and eventually eliminate, the incidence of genetic disorders common to Jewish people, such as Tay–Sachs ...
Taken together, sphingolipidoses have an incidence of approximately 1 in 10,000, but substantially more in certain populations such as Ashkenazi Jews. Enzyme replacement therapy is available to treat mainly Fabry disease and Gaucher disease, and people with these types of sphingolipidoses may live well into adulthood. The other types are ...
Listening to the speakers at the Rally for Israel in Washington, D.C., I heard House Minority Leader Hakeem Jeffries relate “the painful history of the Jewish People.” He said, “For ...